CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3

Estrogen receptor alpha (ERα) expression in ~2/3 breast tumors selects patients for hormonal therapies. Tumors negative for ERα but positive for the progesterone receptor (PR, encoded by PGR) have also been candidates for ER-targeting therapies, as PR expression may reflect undetected ER activity. C...

Ausführliche Beschreibung